November 26, 2021
Article
Besermi is an interferon alfa-2b indicated for the treatment of adults with polycythemia vera.
November 24, 2021
Within 1 or 2 days of injury, therapeutic B cells release a complex mix of specific pro- and anti-inflammatory molecules, which can affect molecular processing and facilitate healing.
Rituximab-pvvr is indicated for the treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, and granulomatosis.
November 22, 2021
Video
Shared insight on treating marginal zone lymphoma with the current treatment armamentarium.
Expert panelists review the pathophysiology of marginal zone lymphoma and reflect on its prevalence as a rare disease.
November 19, 2021
Study finds COVID-19 booster shot was extremely beneficial for all patients with cancer, especially those with a blood cancer.
Hodgkin lymphoma is most common in people between 20 and 40 years of age and those over 55 years of age.
November 17, 2021
The panel also recommends considering risk factors for poor response, including uncontrolled disease, immunoparesis, the number of previous lines of therapy, and patient age.
November 12, 2021
Kymriah is a CD19-directed genetically modified autologous T-cell immunotherapy.
November 11, 2021
No new safety concerns were encountered, which the investigators said support the frontline use of daratumumab plus lenalidomide and dexamethasone for patients with multiple myeloma who are ineligible for transplantation.
